TejasPatilMD

Oncology • Aurora, CO

Physician

Join to view full profile

Dr. Patil is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patil's full profile

Already have an account?

Office
12801 E 17th Ave FL 81018
Aurora, CO 80045
Phone+1 303-724-9238

Fax+1 303-724-3889

Education & Training

University of ColoradoResidency, Internal Medicine, 2013 - 2016
Keck School of Medicine of the University of Southern CaliforniaClass of 2013

Certifications & Licensure

CO State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer Start of enrollment: 2021 Mar 08
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Principal Investigator

Publications & Presentations

PubMed

Development, Review, and Activation of Thoracic Oncology Investigator-Initiated Trials.
David E Gerber, Claire R Wynters, Tanushree Prasad, Ronny K Schnel, Song Zhang
Clinical Cancer Research. 2025-03-17
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitiz...
Tejas Patil, Dexiang Gao, Alexander Watson, Mandy Sakamoto, Yunan Nie
Lung Cancer. 2025-01-01
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.
Margaret Stalker, Connor B Grady, Alex Watts, Wei-Ting Hwang, Krishna Chandrasekhara
JTO Clinical and Research Reports. 2025-01-01

Lectures

Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

‘A Way of Embodying Hope’: 5-Year Lung Cancer Survivors CelebrateMay 13th, 2024
How the Immune System Affects Drug Response in Lung Cancer PatientsMay 10th, 2024
Taking Aim at MET and KRAS in NSCLCOctober 31st, 2022
Join now to see all